Table 2.

Characteristics of the 19 Included Studies

Study and Year	Substudy^{^a}	Drug and Dosing	Duration, Mos	Disease Severity	Treatment Group, No.	Placebo Group, No.	Age, Mean, Y
Budd Haeberlein et al,¹ 2022	ENGAGE and EMERGE	Aducanumab 3 mg/kg q 4 wks	18	MCI or mild AD (MMSE score ≥24)	1,082	1,076	70.4
Budd Haeberlein et al,¹ 2022		Aducanumab 6 mg/kg q 4 wks			1,096	1,076
Salloway et al,²⁵ 2009		Bapineuzumab 0.15 mg/kg q 3 mos	18	Mild to moderate AD (MMSE score 16-26)	31	26	69.1
		Bapineuzumab 0.5 mg/kg q 3 mos			33	28
		Bapineuzumab 1.0 mg/kg q 3 mos			29	26
		Bapineuzumab 2.0 mg/kg q 3 mos			29	27
Salloway et al,²⁹ 2014	Study 301 APOE(−)	Bapineuzumab 0.5 mg/kg q 3 mos	18	Mild to moderate AD (MMSE score 16-26)	314	493	72.5
		Bapineuzumab 1.0 mg/kg q 3 mos			307	493
		Bapineuzumab 2.0 mg/kg q 3 mos			141	493
	Study 302 APOE(+)	Bapineuzumab 0.5 mg/kg q 3 mos			658	432
Lacey et al,⁴⁴ 2015	Study 301 APOE(−)	Bapineuzumab 0.5 or 1.0 mg/kg q 3 mos	18	Mild to moderate AD (MMSE score 16-26)	621	493	72.5
Lacey et al,⁴⁴ 2015	Study 302 APOE(+)	Bapineuzumab 0.5 mg/kg q 3 mos			658	432	72.2
Vandenberghe et al,⁴⁵ 2016	APOE(−)	Bapineuzumab 0.5 mg/kg q 3 mos	18	Mild to moderate AD (MMSE score 16-26)	267	344	70.5
		Bapineuzumab 1.0 mg/kg q 3 mos			263	344
	APOE(+)	Bapineuzumab 0.5 mg/kg q 3 mos	18	Mild to moderate AD (MMSE score 16-26)	654	439
Brashear et al,⁴¹ 2018	Study 301 APOE(−)	Bapineuzumab, 0.5 mg/kg q 3 mos	19	Mild to moderate AD (MMSE score 16-26)	337	524	72-74
		Bapineuzumab, 1 mg/kg q 3 mos			329	524
		Bapineuzumab, 2 mg/kg q 3 mos			141	524
	Study 302 APOE(+)	Bapineuzumab, 0.5 mg/kg q 3 mos			673	448
Cummings et al,⁴⁶ 2018		Crenezumab 15 mg/kg q 4 wks	17	Mild to moderate AD (MMSE score 18-26)	165	82	70.6
Cummings et al,⁴⁶ 2018		Crenezumab 300 mg q 2 wks			122	62
Ostrowitzki et al,²⁶ 2022	CREAD and CREAD2	Crenezumab 60 mg/kg q 4 wks	24	Prodromal or mild AD (MMSE score ≥22)	808	803	70.7
Mintun et al,⁴⁷ 2021	TRAILBLAZER-ALZ	Donanemab 700 mg × 3 then 1,400 mg q 4 wks	19	Early or mild AD	131	126	75.2
Sims et al,⁴² 2023	TRAILBLAZER-ALZ 2	Donanemab 700 mg × 3 then 1,400 mg q 4 wks	18	MCI or mild AD	860	876	74
Ostrowitzki et al,⁴⁸ 2017		Gantenerumab 105 mg q 4 wks	24	Mild AD (MMSE score ≥24)	271	266	70.4
Ostrowitzki et al,⁴⁸ 2017		Gantenerumab 225 mg q 4 wks			260	266
Salloway et al,⁴⁹ 2021		Gantenerumab 225 mg then 1,200 mg q 4 wks	24	Normal but at elevated risk or early AD	52	40	43.8
Swanson et al,¹⁸ 2021		Lecanemab 10 mg/kg biweekly	18	MCI or mild AD	152	237	72^{^b}
Swanson et al,¹⁸ 2021		Lecanemab 10 mg/kg monthly			253	245
Van Dyck et al,¹⁷ 2023		Lecanemab 10 mg/kg biweekly	18	MCI or mild AD	859	875	71.2
Landen et al, ⁵⁰ 2017	Cohort M	Ponezumab 10 mg/kg then 7.5 mg/kg q month	18	Probable AD	12	6	67.8
Landen et al, ⁵⁰ 2017	Cohort Q	Ponezumab 10 mg/kg q 3 mos			12	6
Doody et al,²⁷ 2014	EXPEDITION 1	Solanezumab 400 mg q 4 wks	18	Mild to moderate AD (MMSE score 16-26)	506	506	74.7
Doody et al,²⁷ 2014	EXPEDITION 2	Solanezumab 400 mg q 4 wks			521	519	72.5
Farlow et al,³⁶ 2012		Solanezumab 100 mg q 4 wks	12	Mild to moderate AD (MMSE score 15-26)	10	10	NR
		Solanezumab 100 mg weekly			11	10
		Solanezumab 400 mg q 4 wks			10	10
		Solanezumab 400 mg weekly			11	10
Honig et al,⁵¹ 2018		Solanezumab 400 mg q 4 wks	18	Mild AD (MMSE score 20-26)	1,057	1,072	73.0
Sperling et al,⁴³ 2023		Solanezumab 1,600 mg q 4 wks	54	Normal cognition with amyloid deposition	564	583	72

AD = Alzheimer disease; APOE = apolipoprotein E; APOE(+) = carriers of the ApoE mutation; APOE(−) = noncarriers of the ApoE mutation; MCI = mild cognitive impairment; MMSE = Mini Mental State Examination (score range is 0-30); NR = not reported.
↵a Shown where a study had an identifiable name or subgroup other than by dose.
↵b Median.